Abstract
Purpose
To identify the proportion of reproductive age women with breast cancer that engaged in a fertility preservation discussion and reproductive endocrinology and infertility (REI) consultation.
Methods
This cross-sectional survey recruited women 18–42 years who were diagnosed with breast cancer from 2006 to 2016 by phone or email and asked them to complete an online survey. Demographic characteristics, barriers to FP, utilization of FP consultation, and FP procedures (oocyte and embryo cryopreservation) were analyzed.
Results
A majority of women (64%) did not have FP discussed by any provider. Older women and those who were parents at the time of diagnosis were less likely to engage in a FP discussion. However, there were no significant differences in partner status or cancer stage between women with or without FP discussions. Of the women who desired future children prior to the cancer diagnosis, 93% received chemotherapy; however, only 34% of these women had a consultation with an REI. The most common reasons for declining FP consultation were already having their desired number of children (41%), financial barriers (14%), and concern about delaying cancer treatment and cancer recurrence (12%). Forty percent of women who desired future children and met with an REI pursued FP procedures.
Conclusion
Younger women were more likely to receive FP counseling. FP consultations and procedures were low even in women who desired future fertility, with the predominant barriers being cost, fears concerning a delay in cancer treatment, and future cancer recurrence.
Similar content being viewed by others
References
Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ, Winchester DP. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998;83(6):1262–73. https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1262::aid-cncr28>3.0.co;2-2.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. https://doi.org/10.3322/caac.21208.
Poorvu PD, Frazier AL, Feraco AM, Manley PE, Ginsburg ES, Laufer MR, Partridge AH. Cancer treatment-related infertility: a critical review of the evidence. JNCI Cancer Spectr. 2019;3(1):pkz008. https://doi.org/10.1093/jncics/pkz008.
Silvestris E, Dellino M, Cafforio P, Paradiso AV, Cormio G, D’Oronzo S. Breast cancer: an update on treatment-related infertility. J Cancer Res Clin Oncol. 2020;146(3):647–57. https://doi.org/10.1007/s00432-020-03136-7.
Stensheim H, Cvancarova M, Moller B, Fossa SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129(5):1225–36. https://doi.org/10.1002/ijc.26045.
Selter J, Huang Y, Grossman Becht LC, Palmerola KL, Williams SZ, Forman E, Wright JD. Use of fertility preservation services in female reproductive-aged cancer patients. Am J Obstet Gynecol. 2019;221(4):328 e321-328 e316. https://doi.org/10.1016/j.ajog.2019.05.009.
Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Oktay K. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10. https://doi.org/10.1200/jco.2013.49.2678.
Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, Ubaldi FM. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod. 2012;27(6):1606–12. https://doi.org/10.1093/humrep/des088.
Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71. https://doi.org/10.1210/jc.2015-3878.
Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7. https://doi.org/10.1002/cncr.26459.
Korkidakis A, Lajkosz K, Green M, Strobino D, Velez MP. Patterns of referral for fertility preservation among female adolescents and young adults with breast cancer: a population-based study. J Adolesc Young Adult Oncol. 2019;8(2):197–204. https://doi.org/10.1089/jayao.2018.0102.
Patel P, Kohn TP, Cohen J, Shiff B, Kohn J, Ramasamy R. Evaluation of reported fertility preservation counseling before chemotherapy using the quality oncology practice initiative survey. JAMA Netw Open. 2020;3(7):e2010806. https://doi.org/10.1001/jamanetworkopen.2020.10806%JJAMANetworkOpen.
Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, Albrecht TL. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952–7. https://doi.org/10.1200/jco.2009.23.0250.
Yee S, Buckett W, Campbell S, Yanofsky R, Barr RD. A national study of the provision of oncofertility services to female patients in Canada. J Obstet Gynaecol Can. 2012;34(9):849–58. https://doi.org/10.1016/s1701-2163(16)35384-1.
Jones G, Hughes J, Mahmoodi N, Smith E, Skull J, Ledger W. What factors hinder the decision-making process for women with cancer and contemplating fertility preservation treatment? Hum Reprod Update. 2017;23(4):433–57. https://doi.org/10.1093/humupd/dmx009.
Panagiotopoulou N, Ghuman N, Sandher R, Herbert M, Stewart JA. Barriers and facilitators towards fertility preservation care for cancer patients: a meta-synthesis. Eur J Cancer Care (Engl). 2018;27:e12428-1. https://doi.org/10.1111/ecc.12428.
Cohen L, Hamer J, Helwig C, Fergus K, Kiss A, Mandel R, Warner E. Formal evaluation of PYNK: breast cancer program for young women-the patient perspective. Curr Oncol. 2016;23(2):e102–8. https://doi.org/10.3747/co.23.2773.
Goldfarb SB, Kamer SA, Oppong BA, Eaton A, Patil S, Junqueira MJ, Gemignani ML. Fertility preservation for the young breast cancer patient. Ann Surg Oncol. 2016;23(5):1530–6. https://doi.org/10.1245/s10434-015-5036-8.
Marklund A, Lundberg FE, Eloranta S, Hedayati E, Pettersson K, Rodriguez-Wallberg KA. Reproductive outcomes after breast cancer in women with vs without fertility preservation. JAMA Oncol. 2021;7(1):86–91. https://doi.org/10.1001/jamaoncol.2020.5957%JJAMAOncology.
Chin HB, Howards PP, Kramer MR, Mertens AC, Spencer JB. Which female cancer patients fail to receive fertility counseling before treatment in the state of Georgia? Fertil Steril. 2016;106(7):1763-1771.e1761. https://doi.org/10.1016/j.fertnstert.2016.08.034.
Di Mattei VE, Perego G, Taranto P, Rancoita PMV, Maglione M, Notarianni L, Candiani M. Factors associated with a high motivation to undergo fertility preservation in female cancer patients. Front Psychol. 2021;12:782073. https://doi.org/10.3389/fpsyg.2021.782073.
Oktay K, Harvey BE, Loren AW. Fertility preservation in patients with cancer: ASCO clinical practice guideline update summary. J Oncol Pract. 2018;14(6):381–5. https://doi.org/10.1200/JOP.18.00160.
Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. 2015;33(22):2424–9. https://doi.org/10.1200/JCO.2014.59.3723.
Arecco L, Blondeaux E, Bruzzone M, Ceppi M, Latocca MM, Marrocco C, Lambertini M. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022;37(5):954–68. https://doi.org/10.1093/humrep/deac035%JHumanReproduction.
Rauh-Hain JA, Zubizarreta J, Nitecki R, Melamed A, Fu S, Jorgensen K, . . . Keating NL. Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: a population-based study. Cancer. 2022;128:3243-3253 https://doi.org/10.1002/cncr.34371.
National Summary report SARTcors. 2023 Retrieved May 3, 2023 from https://sartcorsonline.com/CSR/PublicSnapshotReport?ClinicPKID=0&reportingYear=2020.
Salama M, Lambertini M, Christianson MS, Jayasinghe Y, Anazodo A, De Vos M, Woodruff TK. Installing oncofertility programs for breast cancer in limited versus optimum resource settings: empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II. J Assist Reprod Genet. 2022;39(2):505–16. https://doi.org/10.1007/s10815-022-02394-3.
Walter JR, Xu S, Woodruff TK. A call for fertility preservation coverage for breast cancer patients: the cost of consistency. J Natl Cancer Inst, 2017, 109(5) https://doi.org/10.1093/jnci/djx006.
Dolmans MM, von Wolff M, Poirot C, Diaz-Garcia C, Cacciottola L, Boissel N, Andersen CY. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil Steril. 2021;115(5):1102–15. https://doi.org/10.1016/j.fertnstert.2021.03.008.
Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126(1):187–95. https://doi.org/10.1097/aog.0000000000000905.
Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Anderson RA. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811–6. https://doi.org/10.1093/annonc/mdx184.
Anazodo A, Laws P, Logan S, Saunders C, Travaglia J, Gerstl B, Sullivan E. How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care. Hum Reprod Update. 2019;25(2):159–79. https://doi.org/10.1093/humupd/dmy038.
Huang SM, Tseng LM, Yang MJ, Chang A, Lien PJ, Hsiung Y. Developing a web-based oncofertility tool for reproductive-age women with breast cancer based on social support framework. Support Care Cancer. 2022;30(7):6195–204. https://doi.org/10.1007/s00520-022-07046-x.
Speller B, Sissons A, Daly C, Facey M, Kennedy E, Metcalfe K, Baxter NN. An evaluation of oncofertility decision support resources among breast cancer patients and health care providers. BMC Health Serv Res. 2019;19(1):101. https://doi.org/10.1186/s12913-019-3901-z.
Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–33. https://doi.org/10.1016/j.fertnstert.2019.09.013.
Jones GL, Hughes J, Mahmoodi N, Greenfield D, Brauten-Smith G, Skull J, Bekker HL. Observational study of the development and evaluation of a fertility preservation patient decision aid for teenage and adult women diagnosed with cancer: the Cancer, Fertility and Me research protocol. BMJ Open. 2017;7(3):e013219. https://doi.org/10.1136/bmjopen-2016-013219.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by May-Tal Sauerbrun-Cutler, Olivia Recabo, and Christina Raker. The first draft of the manuscript was written by May-Tal Sauerbrun-Cutler and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sauerbrun-Cutler, MT., Pandya, S., Recabo, O. et al. Survey of young women with breast cancer to identify rates of fertility preservation (FP) discussion and barriers to FP care. J Assist Reprod Genet 40, 2003–2011 (2023). https://doi.org/10.1007/s10815-023-02850-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-023-02850-8